Aegean Marine Petroleum Network Inc. (ANW) Reaches $5.55 After 3.00% Down Move, SCYNEXIS (SCYX) Had 6 Analysts Last Week

June 19, 2017 - By Nellie Frank

Among 6 analysts covering Scynexis Inc (NASDAQ:SCYX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Scynexis Inc had 9 analyst reports since August 20, 2015 according to SRatingsIntel. Needham maintained it with “Buy” rating and $16 target in Thursday, August 20 report. Guggenheim initiated the stock with “Buy” rating in Wednesday, August 17 report. H.C. Wainwright initiated SCYNEXIS Inc (NASDAQ:SCYX) on Thursday, October 20 with “Buy” rating. The firm earned “Buy” rating on Monday, October 3 by Brean Capital. The firm has “Buy” rating by Brean Capital given on Monday, March 28. On Tuesday, August 9 the stock rating was upgraded by WBB Securities to “Buy”. As per Tuesday, December 29, the company rating was initiated by WBB Securities. The stock of SCYNEXIS Inc (NASDAQ:SCYX) earned “Strong Buy” rating by WBB Securities on Friday, October 7. The firm has “Outperform” rating given on Monday, November 16 by RBC Capital Markets. See SCYNEXIS Inc (NASDAQ:SCYX) latest ratings:

The stock of Aegean Marine Petroleum Network Inc. (NYSE:ANW) is a huge mover today! About 201,604 shares traded. Aegean Marine Petroleum Network Inc. (NYSE:ANW) has risen 43.45% since June 19, 2016 and is uptrending. It has outperformed by 26.75% the S&P500.The move comes after 5 months negative chart setup for the $228.97 million company. It was reported on Jun, 19 by Barchart.com. We have $5.38 PT which if reached, will make NYSE:ANW worth $6.87M less.

Among 3 analysts covering Aegean Marine Petrol (NYSE:ANW), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Aegean Marine Petrol had 5 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, July 21 by Sidoti. The rating was downgraded by Zacks to “Hold” on Thursday, August 20. The rating was downgraded by Clarkson Capital to “Neutral” on Thursday, May 25. The company was upgraded on Friday, June 2 by Stifel Nicolaus. Stifel Nicolaus downgraded it to “Hold” rating and $9 target in Wednesday, May 24 report.

Aegean Marine Petroleum Network Inc

About 26,774 shares traded. SCYNEXIS Inc (NASDAQ:SCYX) has declined 46.67% since June 19, 2016 and is downtrending. It has underperformed by 63.37% the S&P500.

Investors sentiment increased to 0.91 in Q4 2016. Its up 0.15, from 0.76 in 2016Q3. It improved, as 3 investors sold SCYNEXIS Inc shares while 8 reduced holdings. 3 funds opened positions while 7 raised stakes. 11.25 million shares or 0.56% less from 11.31 million shares in 2016Q3 were reported. Rock Springs Cap Management L P holds 760,000 shares. Blackrock Investment Mgmt Ltd Llc owns 3,496 shares. Geode Capital Mngmt Ltd Liability has 0% invested in SCYNEXIS Inc (NASDAQ:SCYX). Northern Tru holds 0% in SCYNEXIS Inc (NASDAQ:SCYX) or 45,118 shares. Federated Inc Pa holds 3.41M shares or 0.03% of its portfolio. Awm Invest Co holds 0.08% of its portfolio in SCYNEXIS Inc (NASDAQ:SCYX) for 125,000 shares. Tfs Ltd Com owns 18,655 shares for 0.02% of their portfolio. The Texas-based Highland Cap Mgmt Lp has invested 0.06% in SCYNEXIS Inc (NASDAQ:SCYX). Baker Bros Ltd Partnership has 0.01% invested in SCYNEXIS Inc (NASDAQ:SCYX) for 467,600 shares. 500 are held by Us Bank De. Broadfin Ltd owns 1.48M shares. 23,277 are held by Millennium Mngmt Ltd Limited Liability Company. Dafna Cap holds 173,645 shares or 0.49% of its portfolio. Principal Financial Gp reported 0% stake. Deerfield, New York-based fund reported 1.05 million shares.

Since December 21, 2016, it had 2 insider purchases, and 0 selling transactions for $67,750 activity. The insider Taglietti Marco bought $42,250. 15,000 shares were bought by Angulo Gonzalez David, worth $25,500 on Friday, May 12.

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The company has market cap of $41.08 million. The Firm is developing its lead product candidate, SCY-078, as an oral and intravenous drug for the treatment of several fungal infections, including serious invasive fungal infections. It currently has negative earnings. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: